Insmed, Inc.
INSM
$104.47
+0.98%
Insmed, Inc. is a biopharmaceutical company focused on developing and commercializing therapies for serious and rare diseases, operating within the Biotechnology industry. The company has established itself as a specialized player in the respiratory and rare disease space, with two commercial products, Arikayce and Brinsupri, and a clinical pipeline targeting immunology, inflammation, and neuro/rare conditions. The current investor narrative is dominated by a potential turnaround story, as the stock has faced significant pressure, with recent news highlighting a major biotech fund's substantial new investment, signaling institutional confidence in the company's commercial execution and recovery potential despite recent stock weakness.…
INSM
Insmed, Inc.
$104.47
Related headlines
Investment Opinion: Should I buy INSM Today?
Rating: Hold. The core thesis is that while Insmed's commercial growth story is compelling, the extreme valuation, catastrophic cash burn, and severe negative momentum present an asymmetric risk/reward profile that currently favors waiting for clearer signs of sustainability or a more attractive entry point. Analyst sentiment remains bullish, but the lack of a consensus price target highlights the high uncertainty.
The Hold rating is supported by four key data points: 1) The valuation is extreme, with a PS ratio of 61.31x and a forward P/E of 287.9, demanding perfection. 2) Revenue growth, while strong at 152.6% YoY, is volatile and from a low base. 3) Profitability metrics are deeply negative, with an operating margin of -94.6% and a net margin of -210.5%. 4) The stock's technical picture is broken, trading down 45% over six months and near 52-week lows, indicating a lack of near-term catalysts for a reversal.
The two biggest risks that could invalidate a Hold thesis are a successful equity raise that alleviates cash concerns (potentially upgrading to Buy on clarity) or a further deceleration in revenue growth triggering another leg down (downgrading to Sell). This Hold would upgrade to a Buy if the stock stabilizes above key technical resistance (e.g., $110) on sustained quarterly revenue beats and gross margin expansion above 85%, or if the company announces a large, non-dilutive financing deal. It would downgrade to a Sell if quarterly revenue growth decelerates below 50% YoY, if the cash burn rate accelerates, or if the stock breaks decisively below the $90 support level. Relative to its own history and the typical metrics for commercial-stage biotechs, the stock is overvalued, as the current sales multiple prices in success probabilities that may not adequately discount the substantial execution and financing risks.
Sign up to view all
INSM 12-Month Price Forecast
The AI assessment is Neutral with Medium confidence. The investment case is bifurcated: powerful commercial growth versus unsustainable financials. The severe price decline has reset valuation from astronomical levels, but it remains rich for a company burning nearly $1 billion annually. The maintained bullish analyst stance provides a contrarian data point, but the stock's momentum is decisively negative. The stance would upgrade to Bullish on evidence of sustained sequential revenue acceleration coupled with a credible path to reducing the quarterly cash burn rate by at least 25%. It would downgrade to Bearish on a breakdown below the $90 support level or a quarterly revenue miss, either of which would confirm the bear thesis of a broken growth story.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Insmed, Inc.'s 12-month outlook, with a consensus price target around $135.81 and implied upside of +30.0% versus the current price.
Average Target
$135.81
9 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
9
covering this stock
Price Range
$84 - $136
Analyst target range
Analyst coverage appears limited with only 9 analysts providing estimates, and the provided data lacks a consensus price target or recommendation distribution, indicating insufficient analyst coverage for a robust sentiment gauge. The wide range in revenue estimates for the future period, with a low of $5.32 billion and a high of $6.71 billion against an average of $6.16 billion, signals high uncertainty and divergence of opinion on the company's commercial trajectory. The recent institutional ratings from March 2026 show a series of reiterations of 'Buy', 'Overweight', and 'Outperform' ratings from firms like Morgan Stanley, Mizuho, and Wells Fargo, suggesting maintained bullish conviction among covering analysts despite the stock's severe price decline, potentially viewing the weakness as a buying opportunity for the long-term story.
Bulls vs Bears: INSM Investment Factors
The bull and bear cases for Insmed are in stark opposition, creating a high-risk, high-potential-reward investment. The bull case rests on the demonstrated explosive revenue growth from new product launches, strong gross margins, and maintained institutional analyst support. The bear case is anchored by the company's catastrophic cash burn, extreme valuation multiples unsupported by profits, and severe negative price momentum. Currently, the bearish evidence appears stronger, as the stock's technical breakdown and fundamental cash burn are immediate, tangible risks, while the bullish thesis depends entirely on future commercial execution. The single most important tension in the investment debate is whether the company's revenue growth can accelerate fast enough to outpace its massive cash burn before it requires another highly dilutive financing, which would resolve the valuation and sustainability concerns.
Bullish
- Explosive Revenue Growth: Q4 2025 revenue of $263.8 million grew 152.6% year-over-year, driven by the launch of Brinsupri. This demonstrates significant commercial traction and validates the company's product portfolio.
- Strong Institutional Conviction: Recent analyst ratings from March 2026 show reiterated 'Buy' and 'Overweight' calls from major firms like Morgan Stanley and Wells Fargo. This suggests professional confidence in the long-term story despite severe stock price weakness.
- Robust Gross Margin Profile: The company maintains a high gross margin of 82.5% (Q4 2025), indicating strong pricing power and a favorable cost structure for its commercial products, which is a key foundation for future profitability.
- Adequate Short-Term Liquidity: A current ratio of 3.83 provides a significant buffer for near-term operational needs. This liquidity is crucial for funding ongoing clinical development while commercial sales ramp up.
Bearish
- Severe and Accelerating Cash Burn: Trailing twelve-month free cash flow is deeply negative at -$997.6 million, and the Q4 2025 operating margin was -94.6%. This unsustainable burn rate necessitates frequent and dilutive capital raises to fund operations.
- Extreme Valuation Despite Losses: With a negative P/E and a PS ratio of 61.31x, the stock is priced for near-perfect execution. Any commercial stumble or pipeline setback could trigger a severe multiple contraction given the lack of earnings support.
- Persistent Negative Momentum: The stock is down 45.21% over six months and 29.56% over three months, severely underperforming the S&P 500. Trading near its 52-week low of $90.39 indicates a lack of buyer conviction and potential for further downside.
- High Financial Leverage: A debt-to-equity ratio of 1.04 indicates a leveraged balance sheet. This amplifies financial risk in a high-interest-rate environment and limits strategic flexibility.
INSM Technical Analysis
The stock is in a pronounced and sustained downtrend, with a 1-year price change of -3.68% and a more severe 6-month decline of -45.21%. The current price of $95.8 sits near the lower end of its 52-week range, approximately 10% above the 52-week low of $90.39, indicating the stock is in deep value territory but also reflects significant negative momentum and potential fundamental concerns. Recent momentum remains decisively negative, with the stock down 10.81% over the past month and 29.56% over the past three months, severely underperforming the S&P 500 by -11.55% and -44.70% over those respective periods, confirming the downtrend's acceleration and a lack of near-term catalysts for reversal. Key technical support is the 52-week low of $90.39, while resistance lies at the 52-week high of $212.75; a breakdown below support could signal a capitulation phase, while a sustained move above $100 is needed for any stabilization. The stock's beta of 0.774 suggests it has been less volatile than the market during this decline, which is atypical for a biotech and may indicate persistent, non-speculative selling pressure.
Beta
0.77
0.77x market volatility
Max Drawdown
-56.5%
Largest decline past year
52-Week Range
$90-$213
Price range past year
Annual Return
-0.4%
Cumulative gain past year
| Period | INSM Return | S&P 500 |
|---|---|---|
| 1m | -4.0% | -2.2% |
| 3m | -28.1% | +15.8% |
| 6m | -41.3% | +6.4% |
| 1y | -0.4% | +20.9% |
| ytd | -41.0% | +7.7% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
INSM Fundamental Analysis
Revenue is growing but from a low base, with Q4 2025 revenue of $263.8 million representing a 152.6% year-over-year increase; however, this growth is heavily influenced by the launch of Brinsupri and masks a sequential decline from the prior quarter's $142.3 million, indicating potential lumpiness in product sales. The company is deeply unprofitable, with a Q4 2025 net loss of $328.5 million and a gross margin of 82.5%; while the gross margin is robust for a biotech, operating losses remain substantial, with an operating margin of -94.6%, showing that high R&D and SG&A expenses are overwhelming product revenue. The balance sheet shows a debt-to-equity ratio of 1.04, indicating a leveraged capital structure, and trailing twelve-month free cash flow is deeply negative at -$997.6 million; however, the current ratio of 3.83 suggests adequate short-term liquidity, but the persistent cash burn necessitates ongoing external financing to fund operations and clinical development.
Quarterly Revenue
$263843000.0B
2025-12
Revenue YoY Growth
+1.52%
YoY Comparison
Gross Margin
+0.82%
Latest Quarter
Free Cash Flow
$-997575000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is INSM Overvalued?
Given the company's negative net income and EBITDA, the primary valuation metric selected is the Price-to-Sales (PS) ratio. The trailing PS ratio is an extremely high 61.31x, while the Enterprise Value-to-Sales (EV/Sales) is 24.68x, indicating the market is valuing the company based on future revenue potential rather than current profitability. A direct peer comparison is not available from the provided data, but such elevated sales multiples are typically reserved for companies with hyper-growth expectations or transformative pipeline assets, suggesting the market is pricing in significant future commercial success for Insmed's portfolio. Historically, the stock's own PS ratio has fluctuated wildly, from a low near 35.65x in early 2021 to a high of 214.24x in Q3 2025; the current 61.31x sits below the recent peak but remains well above the lower end of its historical range, indicating expectations, while tempered from recent highs, are still optimistic relative to the company's longer-term history.
PE
-27.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range -28x~-3x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-32.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks are severe and center on cash sustainability. The company burned -$997.6 million in free cash flow over the trailing twelve months, with a Q4 2025 operating margin of -94.6%. With a debt-to-equity ratio of 1.04, the balance sheet is already leveraged, limiting its ability to borrow further. Revenue, while growing at 152.6% YoY, showed a sequential decline from Q3 to Q4 2025, indicating potential lumpiness and raising execution risk. The company's survival is contingent on its ability to rapidly scale sales to offset these enormous losses or successfully access equity markets, which at current depressed prices would be highly dilutive.
Market & Competitive Risks are elevated due to valuation compression and sector sentiment. Trading at a PS ratio of 61.31x and an EV/Sales of 24.68x, the stock is priced for flawless hyper-growth. Any disappointment in quarterly sales, pipeline progress, or a broader de-rating of loss-making biotech stocks could trigger a sharp multiple contraction. The stock's beta of 0.774 is misleading; its 45% six-month decline amid a rising market shows it faces severe company-specific, non-systematic selling pressure. Competitive threats in its core respiratory and rare disease markets could also pressure pricing and market share for Arikayce and Brinsupri.
Worst-Case Scenario involves a 'failure to launch' narrative taking hold. This would be triggered by a significant quarterly revenue miss or a clinical pipeline setback, leading to a loss of analyst confidence and institutional support. Coupled with the inability to secure non-dilutive financing, this could force a deeply discounted equity offering. In this adverse scenario, the stock could re-test and break below its 52-week low of $90.39, potentially falling towards levels implied by a more normalized biotech sales multiple during a crisis, representing a downside of -35% to -50% from the current price near $95.8. The historical max drawdown of -56.54% provides a benchmark for the potential depth of loss.
FAQ
The key risks are, in order of severity: 1) Financial Sustainability Risk: The company's massive cash burn (-$997.6M TTM) necessitates frequent capital raises, risking severe shareholder dilution. 2) Execution & Commercialization Risk: Revenue growth, while strong year-over-year, showed a sequential decline, and future estimates vary widely, indicating high uncertainty. 3) Valuation Risk: The extreme PS ratio of 61.31x leaves the stock vulnerable to multiple compression if growth moderates. 4) Leverage Risk: A debt-to-equity ratio of 1.04 adds financial strain in a high-rate environment. These risks are interconnected and create a precarious situation for the company.
The 12-month forecast is highly uncertain, with three distinct scenarios. The Base Case (50% probability) sees the stock trading between $110 and $140 as growth continues but cash burn concerns linger, leading to sideways action. The Bull Case (25% probability) targets $180 to $212, requiring flawless commercial execution and a favorable financing event. The Bear Case (25% probability) sees the stock falling to $70-$90 on a growth slowdown or a dilutive capital raise. The most likely scenario is the Base Case, which assumes the company meets low-end growth expectations but continues to face significant financial headwinds. The wide target ranges reflect the stock's binary risk/reward profile.
Based on conventional metrics, INSM is significantly overvalued. It has no P/E due to losses, and its Price-to-Sales ratio of 61.31x is extremely high, even for a growth biotech. The Enterprise Value-to-Sales of 24.68x is also rich. This valuation implies the market expects near-perfect execution and hyper-growth to justify the price. Compared to its own history, the PS ratio has compressed from a peak of 214x but remains above its lower historical range. The stock is not cheap; it is priced for success, leaving little margin for error. Any stumble would likely cause a sharp de-rating.
INSM is a speculative buy only for investors with a very high risk tolerance and a long-term investment horizon. The potential upside is significant if its commercial products achieve blockbuster status, as reflected in analyst bullishness. However, the downside risk is severe, with the stock down 45% in six months, burning nearly $1 billion annually, and trading on extreme sales multiples. It could be a good buy for a venture-capital-style investor willing to bet on the commercial turnaround, but it is a poor choice for most retail investors seeking capital preservation or stable returns. A more prudent approach would be to wait for evidence of sustained revenue growth and a reduction in cash burn.
INSM is strictly a long-term, speculative investment with a minimum suggested holding period of 3-5 years. The company is in the capital-intensive phase of scaling its commercial operations and advancing its clinical pipeline; profitability is years away. The stock's high volatility (evidenced by a 56% max drawdown) and lack of a dividend make it unsuitable for short-term trading or income investors. Only investors with the patience and risk capacity to wait for the company's financial story to potentially resolve favorably should consider a position. Short-term price movements are likely to be driven by binary events like earnings reports or financing news, which are difficult to predict.